Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 9 de 9
1.
J Thromb Haemost ; 9(9): 1744-51, 2011 Sep.
Article En | MEDLINE | ID: mdl-21726405

BACKGROUND: Binding of von Willebrand factor (VWF) multimers of ultra-large size to platelets is considered the triggering mechanism of microvascular thrombosis in thrombotic thrombocytopenic purpura (TTP). OBJECTIVE: To assess the potential of VWF-related measurements as markers of disease activity and severity in TTP. METHODS: VWF antigen (VWF:Ag), platelet glycoprotein-Ib-α binding-conformation (GPIb-α/BC) and multimeric pattern were investigated in 74 patients with acquired TTP during acute disease, remission or both and 73 healthy controls. In patients with both acute and remission samples available, VWF ristocetin co-factor activity (VWF:RCo) and collagen binding (VWF:CB) were also measured. The relationships of study measurements with the presence of acute disease and remission and with markers of disease severity were assessed. RESULTS: VWF:Ag and VWF-GPIb-α/BC were higher in TTP patients than controls (P < 0.001 and 0.004). However, there was no statistically significant difference in VWF-GPIb-α/BC between samples obtained during acute TTP and remission. Larger VWF multimers were frequently lacking in acute TTP patients, who displayed ultra-large multimers at remission. The degree of loss of larger VWF multimers correlated with the degree of abnormality of hemoglobin, platelet counts and serum lactate dehydrogenase (LDH) and was associated with low levels of both VWF:RCo/Ag and VWF:CB/Ag ratios. CONCLUSIONS: In TTP the platelet-binding conformation of VWF is not exclusively present in acute disease, nor is it associated with its clinical and laboratory severity. The loss of larger VWF multimers, accompanied by low VWF:RCo/Ag and VWF:CB/Ag ratio values, represents an index of disease activity and severity of acute TTP in patients with severe ADAMTS-13 deficiency.


Blood Platelets/physiology , Purpura, Thrombotic Thrombocytopenic/blood , von Willebrand Factor/chemistry , von Willebrand Factor/physiology , ADAM Proteins/blood , ADAM Proteins/deficiency , ADAMTS13 Protein , Acute Disease , Case-Control Studies , Collagen/blood , Humans , Membrane Glycoproteins/blood , Membrane Glycoproteins/chemistry , Platelet Glycoprotein GPIb-IX Complex , Protein Binding , Protein Conformation , Protein Multimerization , Retrospective Studies , von Willebrand Factor/metabolism
2.
J Thromb Haemost ; 9(5): 953-8, 2011 May.
Article En | MEDLINE | ID: mdl-21352469

BACKGROUND: Aortic stenosis patients often show bleeding complications. Previously, a prolonged platelet function analyzer (PFA-100) closure time was observed with plasma of severe aortic stenosis patients. To elucidate a possible role of circulating preactivated von Willebrand factor (VWF), we determined the level of VWF in its active, platelet-binding conformation in plasma of patients with aortic stenosis. PATIENTS/METHODS: Sixty-two aortic stenosis patients were included in this study. VWF and related parameters were measured, and the results were related to severity of aortic stenosis. RESULTS: VWF activation factor, indicating the proportion of circulating VWF able to bind to platelets, correlated negatively with peak transvalvular gradient and PFA-100 closure time. No correlation was observed between ADAMTS13 activity and peak transvalvular gradient or PFA-100 closure time. Both VWF antigen and VWF propeptide levels were significantly higher in patients with mild and moderate aortic stenosis, but not in those with severe stenosis. CONCLUSIONS: Our data demonstrate that the aortic pressure gradient is inversely associated with VWF activation factor, but not with VWF antigen or VWF multimerization in patients with aortic stenosis. These findings might have implications for the bleeding observed in patients with aortic stenosis.


Aortic Valve Stenosis/blood , Aortic Valve Stenosis/pathology , von Willebrand Factor/biosynthesis , ADAM Proteins/blood , ADAMTS13 Protein , Aged , Female , Hemorrhage , Hemostasis , Humans , Male , Middle Aged , Peptides/chemistry , Platelet Function Tests , Shear Strength , Stress, Mechanical , Surveys and Questionnaires
5.
J Thromb Haemost ; 8(5): 1098-106, 2010 May.
Article En | MEDLINE | ID: mdl-20158601

SUMMARY BACKGROUND: During invasive meningococcal disease, severe thrombocytopenia is strongly associated with a poor outcome. OBJECTIVES: In order to elucidate the pathophysiological mechanism behind the development of thrombocytopenia, we studied the role of von Willebrand factor (VWF) in meningococcal disease. PATIENTS/METHODS: Thirty-two children with severe meningococcal disease admitted to our university hospital were included in this study. VWF and related parameters were measured and results were correlated with the development of shock and thrombocytopenia. RESULTS: At admission, all patients had increased levels of (active) VWF and VWF propeptide. The highest VWF propeptide levels were observed in patients with shock, indicating acute endothelial activation. Although VWF propeptide levels in patients with shock, with or without thrombocytopenia, were similar, increased active VWF was significantly lower in patients with thrombocytopenia as compared with patients without thrombocytopenia. ADAMTS13 was moderately decreased. However, the VWF multimeric pattern was minimally increased. We assume that these findings are explained by VWF consumption and perhaps by granzyme B (GrB). In vitro experiments showed that GrB is able to cleave VWF multimers in plasma, whereas GrB was high in patients with shock, who developed thrombocytopenia. CONCLUSIONS: Our results demonstrate that consumption of VWF, derived from endothelial cells, could be a key feature of meningococcal disease and primary to the development of thrombocytopenia during shock.


Granzymes/metabolism , Meningitis, Bacterial/metabolism , Thrombocytopenia/metabolism , von Willebrand Factor/metabolism , ADAM Proteins/metabolism , ADAMTS13 Protein , Child , Child, Preschool , Female , Humans , Infant , Male , Meningitis, Bacterial/complications , Meningitis, Bacterial/enzymology , Thrombocytopenia/complications , Thrombocytopenia/enzymology
6.
J Thromb Haemost ; 3(10): 2228-37, 2005 Oct.
Article En | MEDLINE | ID: mdl-16194200

BACKGROUND: von Willebrand disease (VWD) is a bleeding disorder caused by the decrease of functional von Willebrand factor (VWF). Low levels of VWF can result from decreased synthesis, impaired secretion, increased clearance or combinations thereof. Several mutations lead to impaired synthesis or secretion of VWF, however, little is known about the survival of VWF in the circulation. OBJECTIVES: To evaluate the effect of several VWF mutations on VWF clearance. PATIENTS/METHODS: The effect of three cysteine-mutations (C1130F, C1149R or C2671Y) on the in vivo survival of VWF was studied in patients carrying these mutations and in a VWF-deficient mice model. RESULTS: In patients carrying these mutations, we observed increased propeptide/mature VWF ratios and rapid disappearance of VWF from the circulation after desmopressin treatment. Detailed analysis of in vivo clearance of recombinant VWF in a VWF-deficient mice model revealed a fourfold increased clearance rate of the mutants. The mutations C1130F, C1149R and C2671Y are each associated with reduced survival of VWF in the circulation. Detailed analysis of the recombinant mutant VWF demonstrated that increased clearance was not due to increased proteolysis by ADAMTS-13. We did not identify functional or structural characteristics that the mutant proteins have in common and could be associated with the phenomenon of increased clearance. CONCLUSIONS: Cysteine-mutations in VWF may result in reduced in vivo survival. The observation that various mutations are associated with increased in vivo clearance may have major implications for the therapeutic strategies that rely on the rise of endogenous VWF after desmopressin administration.


Cysteine/genetics , Mutation, Missense , von Willebrand Diseases/genetics , von Willebrand Factor/genetics , von Willebrand Factor/metabolism , ADAMTS13 Protein , Animals , Deamino Arginine Vasopressin/pharmacology , Humans , Metabolism , Metalloendopeptidases/metabolism , Mice , Mice, Knockout , Recombinant Proteins/pharmacokinetics , von Willebrand Diseases/blood , von Willebrand Factor/analysis
7.
J Thromb Haemost ; 3(10): 2274-80, 2005 Oct.
Article En | MEDLINE | ID: mdl-16150043

In humans, fulminant hepatic failure (FHF) is frequently associated with increased factor VIII (FVIII) levels, despite widespread liver cell death. The mechanisms leading to increased FVIII levels and cellular sites of this enhanced FVIII production are poorly understood. We studied the effect of total hepatectomy in pigs, a large-animal model of FHF, on the expression of plasma and tissue FVIII during 24-hour follow-up. Tissue FVIII expression was determined before and 24 h after hepatectomy, both at the mRNA level and immunohistochemically. The expression of plasma and tissue von Willebrand factor (VWF), the natural stabilizing carrier protein of FVIII, was also measured. Total hepatectomy elicited a gradual and sustained twofold elevation of circulating FVIII, whereas FVIII mRNA levels in various organs did not increase after hepatectomy. The half-life of FVIII increased from 7.7 to 10.3 h and VWF levels were also elevated in anhepatic pigs. The increase in the half-life of FVIII and increased levels of VWF were not sufficient to explain the rise in plasma FVIII levels. At the protein level, prominent changes in the cellular distribution of FVIII were seen in spleen and kidney. These observations suggest that in this model of FHF the lack of hepatic FVIII synthesis is adequately compensated by other organs, notably spleen and kidneys.


Factor VIII/analysis , Liver Failure, Acute , Animals , Factor VIII/genetics , Half-Life , Hepatectomy , Immunohistochemistry , Kidney/chemistry , Liver/chemistry , Liver Failure, Acute/etiology , Models, Animal , RNA, Messenger/analysis , Spleen/chemistry , Swine , Tissue Distribution , von Willebrand Factor/analysis
8.
Thromb Haemost ; 86(3): 855-61, 2001 Sep.
Article En | MEDLINE | ID: mdl-11583319

Previous studies have shown that factor VIII (FVIII) is expressed by multiple tissues. However, little is known about its cellular origin or its level of expression in different organs. In the present study, we examined FVIII gene expression in different tissues on a quantitative basis. Most of the tissues, especially liver and kidney, expressed high levels of FVIII mRNA compared to their level of expression of other hemostatic proteins, including von Willebrand factor (VWF). This was unexpected since FVIII is a trace protein. In situ hybridization analysis confirmed that liver and kidney were rich in FVIII mRNA. In the liver, a clear hybridization signal was detected in cells lining the sinusoids. FVIII mRNA analysis of purified liver cells confirmed the expression of FVIII mRNA by sinusoidal endothelial cells and Kupffer cells. Low but significant levels of FVIII mRNA were also detected in the hepatocytes. VWF mRNA was not detectable in these cells. Similarly, immunohistochemical staining of liver tissue revealed that FVIII protein is primarily associated with sinusoidal cells. VWF protein was predominantly located in the endothelium of larger vessels. In the kidney, FVIII synthesis was localized to the glomeruli and to tubular epithelial cells. Taken together, these results suggest that besides hepatocytes, non-parenchymal cells (e.g. sinusoidal endothelial cells) contribute to FVIII synthesis. VWF synthesis is primarily confined to extra-hepatic tissues.


Factor VIII/biosynthesis , Animals , Brain/metabolism , Endothelium, Vascular/metabolism , Factor VIII/genetics , Female , Gene Expression Profiling , Gene Expression Regulation , Immunochemistry , In Situ Hybridization , Kidney/cytology , Kidney/metabolism , Liver/cytology , Liver/metabolism , Lung/metabolism , Male , Mice , Mice, Inbred C57BL , Myocardium/metabolism , Organ Specificity , Polymerase Chain Reaction , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Thromboplastin/biosynthesis , Thromboplastin/genetics , Urokinase-Type Plasminogen Activator/biosynthesis , Urokinase-Type Plasminogen Activator/genetics , von Willebrand Factor/biosynthesis , von Willebrand Factor/genetics
9.
Biophys Chem ; 90(3): 249-53, 2001 May 18.
Article En | MEDLINE | ID: mdl-11407642

In this paper a flux-coupling model of photosynthesis is presented. By requiring minimum entropy production, it is found that the photosynthetic efficiency is essentially given by the square root of D/lambda. D and lambda are the diffusion coefficient and thermal conductivity of the rate-limiting processes in the chloroplast, respectively. For experimental values of D and lambda, the efficiency is found to be 2.4-7.5%, with a likely value of 6.1%, whereas C4-plants are known to have an efficiency of 6.2%. We conclude that the process of photosynthesis is in quantitative agreement with the principle of minimum entropy production.


Entropy , Photosynthesis , Diffusion , Kinetics , Models, Chemical
...